Q&A With US FDA Commissioner Scott Gottlieb

US FDA Commissioner Scott Gottlieb sat down with the Pink Sheet and Medtech Insight reporters for an exclusive chat about his ongoing regulatory work and plans for the future.

Gottlieb

Promoting competition among new drugs does not necessarily mean encouraging development of so-called "me-too" products and the limited band-width of FDA's document redaction effort may mean the release of complete response letters is not prioritized, FDA Commissioner Scott Gottlieb told the Pink Sheet in a recent interview.

Gottlieb spoke Nov. 3 at the National Press Club in Washington, D.C. (Also see "Gottlieb Promotes 'Team' Work For...

More from Agency Leadership

More from Pink Sheet